


I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

#6

Commissioner for Patents
Washington, D.C. 20231
on July 2, 2001
Date of Deposit



Thomas J. Wrona, Reg. No. 44,410

Name of applicant, assignee or
Registered Representative

Signature

Date of Signature

Case No. 10114/6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Peng G. Wang et al.	
Serial No.: 09/758,525	Attention: Manager,
	Application Branch
Filed: January 10, 2001	
For: Glycoconjugate Synthesis Using a PathwayEngineered Organism	

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

BOX SEQUENCE LISTING

Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

Submitted herewith is a sequence listing as part of the above-captioned patent application. Applicants' representative states that the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicants' representative hereby verifies that the information on the accompanying diskette is identical to the written sequence listing. The enclosed sequence listing does not include any new matter which goes beyond the disclosure in the captioned application as filed.

Respectfully submitted,

Dated: July 2, 2001


Thomas J. Wrona
Registration No. 44,410
Agent for Applicants

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, IL 60610
(312)321-4200

105020" 6335260

#6



SEQUENCE LISTING

<110> Wang, Peng G.
Chen, Xi
Zhang, Wei
Liu, Ziyue

<120> GLYCOCONJUGATE SYNTHESIS USING A PATHWAY-ENGINEERED ORGANISM

<130> 10114-6

<140> 09/758,525

<141> 2001-01-10

<160> 23

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Nucleotide-binding-protein motif. Xaa represents any amino acid.

<400> 1

Gly Xaa Xaa Gly Xaa Xaa Gly
1 5

<210> 2

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: galK primer

<400> 2

gatcatatga gtctgaaaga aaaaacac

28

<210> 3

<211> 30

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: galK primer

 <400> 3
 cgcggatcct cagcactgtc ctgctccttg 30

 <210> 4
 <211> 35
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: galT primer

 <400> 4
 ggatccatat gactagtatg acgcaattta atccc 35

 <210> 5
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: galT primer

 <400> 5
 agcggatcct tacactccgg attcgcg 27

 <210> 6
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: galU primer

 <400> 6
 ggatcctcga gatggctgcc attaatacg 29

 <210> 7
 <211> 36